Orchard Therapeutics Balance Sheet Health
Financial Health criteria checks 4/6
Orchard Therapeutics has a total shareholder equity of $80.3M and total debt of $25.6M, which brings its debt-to-equity ratio to 31.9%. Its total assets and total liabilities are $202.3M and $122.0M respectively.
Key information
31.9%
Debt to equity ratio
US$25.59m
Debt
| Interest coverage ratio | n/a |
| Cash | US$125.41m |
| Equity | US$80.26m |
| Total liabilities | US$122.01m |
| Total assets | US$202.27m |
Recent financial health updates
Is Orchard Therapeutics (NASDAQ:ORTX) A Risky Investment?
Mar 10
Orchard Therapeutics (NASDAQ:ORTX) Has Debt But No Earnings; Should You Worry?
Jun 14Recent updates
Orchard Therapeutics: Still An Attractive Merger Arbitrage Opportunity With A CVR
Jan 19Revenues Working Against Orchard Therapeutics plc's (NASDAQ:ORTX) Share Price
May 09Is Orchard Therapeutics (NASDAQ:ORTX) A Risky Investment?
Mar 10Orchard Therapeutics: Gene Therapy For Rare Child Disease
Aug 19Orchard Therapeutics GAAP EPS of -$0.40 misses by $0.14, revenue of $4.37M beats by $1.19M
Aug 04Orchard Therapeutics: Shadow Of Former Glory
Jan 20Orchard Therapeutics: Cutting-Edge Science Beset With A Pioneer's Typical Hurdles
Aug 16Orchard Therapeutics (NASDAQ:ORTX) Has Debt But No Earnings; Should You Worry?
Jun 14What Is The Ownership Structure Like For Orchard Therapeutics plc (NASDAQ:ORTX)?
Feb 03Orchard Therapeutics appoints Braden Parker as chief commercial officer
Jan 29Orchard Therapeutics' OTL-200 wins FDA's RMAT status
Jan 14Orchard Therapeutics' OTL-103 US application for immunodeficiency disorder, pushed to 2022
Jan 12Is Orchard Therapeutics plc (NASDAQ:ORTX) Trading At A 26% Discount?
Jan 08Orchard Therapeutics' MLD gene therapy wins European nod
Dec 21Our View On Orchard Therapeutics
Dec 17Reflecting on Orchard Therapeutics' (NASDAQ:ORTX) Share Price Returns Over The Last Year
Dec 11Orchard's gene therapy shows encouraging action in a rare neurometabolic disorder study
Dec 08Orchard Therapeutics (ORTX) Investor Presentation - Slideshow
Nov 22Financial Position Analysis
Short Term Liabilities: ORTX's short term assets ($153.9M) exceed its short term liabilities ($49.4M).
Long Term Liabilities: ORTX's short term assets ($153.9M) exceed its long term liabilities ($72.6M).
Debt to Equity History and Analysis
Debt Level: ORTX has more cash than its total debt.
Reducing Debt: ORTX's debt to equity ratio has increased from 0% to 31.9% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ORTX has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: ORTX has less than a year of cash runway if free cash flow continues to reduce at historical rates of 1.6% each year